Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
RESEARCH TOOLSreports
Holding HOWL?
Track your performance easily
HOWL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.38 - $8.19
Previous Close$1.59
Volume606.11K
Average Volume (3M)750.75K
Market Cap
$69.96M
Enterprise Value-$16.06M
Total Cash (Recent Filing)$122.80M
Total Debt (Recent Filing)$36.78M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Mar 20, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding44,563,153
10 Day Avg. Volume296,590
30 Day Avg. Volume750,745
Standard Deviation0.26
R-Squared0.00301
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.79
Price to Sales (P/S)20.66
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.72
Enterprise Value/Gross Profit-10.28
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$13.33Price Target Upside738.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Werewolf Therapeutics News
PremiumCompany Announcements
Werewolf Therapeutics Advances Innovative Cytokine Therapies
PremiumStock Analysis & Ideas
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Werewolf Therapeutics Reports Promising WTX-330 Trial OutcomesBulls Say, Bears Say
Bulls Say
Drug Development And Clinical TrialsThe presentation of positive initial results for WTX-330, showing significant tumor reduction, highlights the potential effectiveness of Werewolf's drug development.
Innovative Therapeutic ApproachWerewolf’s early clinical results—including durable responses as a monotherapy and in combination with pembrolizumab (WTX-124), as well as manageable safety profiles (WTX-124, WTX-330)—position the company as a leader in the cytokine immunotherapy space.
Partnership And Financial StabilityThe collaboration with Jazz Pharmaceuticals and a strong cash position are seen as strengths that enhance Werewolf's investment appeal.
Bears Say
Clinical TrialsA melanoma patient dosed at 12 mg progressed at week 16 with new lesions near the sternum and portal vein identified.
EarningsWerewolf reported no revenues for 3Q24, which could be a concern for potential investors looking for immediate earnings.
Product DevelopmentWTX-330's overall breadth and depth of response was modest with suboptimal durability, and coincided with on-mechanism dose-limiting toxicities and high-grade adverse events.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HOWL FAQ
What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $1.38 and its highest was $8.19 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Currently, no data Available
When is Werewolf Therapeutics’s upcoming earnings report date?
Werewolf Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 88 days.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.025.
Is Werewolf Therapeutics overvalued?
According to Wall Street analysts Werewolf Therapeutics’s price is currently Undervalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 44,563,152 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went down -8.197%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Among the largest hedge funds holding Werewolf Therapeutics’s share is RA Capital Management. It holds Werewolf Therapeutics’s shares valued at 13M.
---
Werewolf Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (738.36% Upside)
$13.33 (738.36% Upside)
Blogger Sentiment
Bullish
HOWL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 125.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.79%
12-Months-Change
Fundamentals
Return on Equity
-61.56%
Trailing 12-Months
Asset Growth
-20.61%
Trailing 12-Months
Company Description
Werewolf Therapeutics
Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
---
HOWL Stock 12 Month Forecast
Average Price Target
$13.33
▲(738.36% Upside)
Technical Analysis
Best Analysts Covering HOWL
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
+3.51%
reiterated a buy rating 3 months ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +3.51% per trade.
---